A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine theSafety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a fenretinide phospholipidsuspension (12.5 mg/mL) for Intravenous Infusion
Study of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Sponsor: SciTech Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAU7936
U.S. Govt. ID: NCT04234048
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see what effects, good and/or bad, the study drug, ST-001, has on you and your cancer, to find the best dose for treating your condition, and to see how safe ST-001 is for participants with your condition. This study will help us understand more about whether intravenous (injected into the vein) ST-001, will be a useful study treatment for subjects with Relapsed/Refractory T-cell Non-Hodgkin Lymphoma (T-Cell NHL). Relapsed or refractory disease means your disease that has come back after initial treatment or did not respond to initial treatment. Approximately 46 patients will be enrolled across 5-10 clinical sites nationwide. ST-001 has not been studied in human clinical trials yet.
Barbara Pro, MD
Do You Qualify?
Are you at least 18 years of age or older? Yes No
Do you have relapsed or refractory disease after at least two prior systemic drug treatment regimens? Yes No
Are you willing to come into the clinic for additional evaluations and treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator